New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
Trial shows promising early results for HLD-0915, a first-in-class regulated induced proximity targeting chimera (RIPTAC) treatment
Metastatic castration-resistant prostate cancer (mCRPC) is a hard-to-treat prostate cancer that no longer responds to standard hormone therapy
Preliminary data suggest HLD-0915 has a favorable safety profile with evidence of tumor shrinkage and PSA decline in mCRPC patients
HLD-0915 received FDA fast track...
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal...